Sungen Core Technologies
Molecular Discovery Platform
A molecular discovery platform leverages advanced technologies like synthetic libraries, hybridoma, Bispecific Antibody, single B cell sorting, and AI to identify and develop novel antibodies efficiently.
Pilot R & D and Production Platform
Our pilot R&D and production platform excels in small-scale processes and Fed-Batch culture, using advanced purification technologies like affinity and ion exchange chromatography. We produce high-purity antibody and protein solutions, and various drug products with industry-leading filling accuracy.
Quality Control Platform
A quality control platform conducts comprehensive tests including molecular weight, sequence coverage, disulfide bond location, peptide mapping, N/C terminal sequencing, post-translational modifications, DAR value, and unknown peak identification.
Our antibody discovery platform utilizes state-of-the-art technologies to identify and develop high-affinity antibodies efficiently. This platform encompasses a range of methodologies, including phage display, hybridoma technology, and single B-cell cloning, ensuring a diverse and robust antibody repertoire.
Furthermore, we offer both antibody discovery platforms and bispecific antibody platforms to cater to the diverse needs of our clients. These platforms facilitate the generation of bispecific antibodies, which possess dual specificity for two different targets, offering unprecedented therapeutic potential.
Among our specialized offerings is the Regeneron bispecific platform. This platform leverages Regeneron's proprietary VelocImmune technology, renowned for its ability to produce high-affinity, fully human antibodies with exceptional specificity and potency. By utilizing this platform, we can create bispecific antibodies with enhanced therapeutic properties and potential for treating a wide range of diseases.
If you want to know more about method of preparation of monoclonal antibodies, please contact us.
You must be logged in to post a comment.